МЕТОДЫ ЯДЕРНОЙ МЕДИЦИНЫ В ДИАГНОСТИКЕ НЕЙРОЭНДОКРИНЫХ ОПУХОЛЕЙ
Аннотация
Обзор литературы посвящен анализу радиофармацевтических препаратов (РФП) и современных радиоизотопных технологий для диагностики, стадирования и оценки прогноза при нейроэндокринных опухолях различных локализаций. На основании результатов клинических исследований продемонстрированы диагностические возможности сцинтиграфии и позитронной эмиссионной томографии (ПЭТ) при карциноидах кишки, поджелудочной железы и легких, медуллярном раке щитовидной железы, феохромоцитоме и параганглиоме и обоснован выбор РФП. Перечислены причины ложноположительных и ложноотрицательных результатов сцинтиграфии и ПЭТ.
Об авторах
Д. В. Рыжкова
ФГБУ «Федеральный центр сердца, крови и эндокринологии им. В.А. Алмазова» Министерства здравоохранения Российской Федерации
Россия
Россия
Д. Н. Тихонова
ФГБУ «Федеральный центр сердца, крови и эндокринологии им. В.А. Алмазова» Министерства здравоохранения Российской Федерации
Россия
Россия
Е. Н. Гринева
ФГБУ «Федеральный центр сердца, крови и эндокринологии им. В.А. Алмазова» Министерства здравоохранения Российской Федерации
Россия
Россия
Список литературы
1. Афанасьев С.Г., Авдеев С.В., Пак А.В. и др. Опыт лечения АКТГ-эктопированной опухоли легкого//Сибирский онкологический журнал. 2009. № 6 (36). С. 83-86
2. Егоров А.В., Кузин Н.М. Вопросы диагностики нейроэндокринных опухолей поджелудочной железы//Практическая онкология. 2005. Т. 6, № 4. С. 206-212
3. Имянитов Е.Н. Эпидемиология и биология нейроэндокринных опухолей//Практическая онкология. 2005. Т. 6, № 4. С. 202-205
4. Ларенков А.А., Кодина Г.Е., Брускин А.Б. Радионуклиды галлия в ядерной медицине: радиофармацевтические препараты на основе изотопа 68Ga//Медицинская радиология и радиационная безопасность. 2011. Т. 56, № 5. С. 56-73
5. Латыпов В.Р., Попов О.С., Вусик А.Н., Латыпова В.Н., Гейдаров Р.Я. Особенности и результаты хирургического лечения пациентов с опухолями надпочечников//Сибирский онкологический журнал. 2010. № 1 (37). С. 56-60
6. Ширяев С.В. Эмиссионная томография в комплексной диагностике опухолевых поражений печени: Автореф. дис. … д-ра мед. наук. М., 2009. 23 с
7. Ahlstroem H., Eriksson B., Bergstroem M. et al. Pancreatic neuroendocrine tumours: Diagnosis with PET//Radiology. 1995. Vol. 195. P. 333-337
8. Alexander K., Putzer D., Uprimny C. et al. Functional imaging in phaeochromocytoma and neuroblastoma with 68Ga-DOTA-Tyr3-octreotide positron emission tomography and 123I-metaiodobenzylguanidine//Eur. J. Nucl. Med. Mol. Imaging. 2011. Vol. 38. P. 865-887
9. Ambrosini V., Tomassetti P., Castellucci P. et al. Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-enteropancreatic and lung neuro-endocrine tumours//Eur. J. Nucl. Med. Mol. Imaging. 2008. Vol. 35. P. 1431-1438
10. Antunes P., Ginj M., Zhang H. et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals//Eur. J. Nucl. Med. Mol. Imaging. 2007. Vol. 34. P. 982-993
11. Bansal R., Tierney W., Carpenter S. et al. Cost effectiveness of EUS for preoperative localization of pancreatic endocrine tumors//Gastrointest. Endoscop. 1999. Vol. 49 (1). P. 19-25
12. Beheshti M., Pеocher S., Vali R. et al. The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT//Eur. Radiol. 2009. Vol. 19. P. 1425-1434
13. Binderup T., Knigge U., Loft A., Federspiel B. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors//Clin. Cancer Res. 2010. Vol. 16 (3). P. 978-985
14. Esser J.P., Krenning E.P., Teunissen J.J. et al. Comparison of [(177) Lu-DOTA(0),Tyr (3)]octreotate and [(177)Lu-DOTA(0),Tyr (3)]octreotide: which peptide is preferable for PRRT?//Eur. J. Nucl. Med. Mol. Imaging. 2006. Vol. 33. P. 1346-1351
15. Ezziddin S., Logvinski T., Yong-Hing C. et al. Factors predicting tracer uptake in somatostatin receptor and MIBG scintigraphy of metastatic gastroenteropancreatic neuroendocrine tumors//J. Nucl. Med. 2006. Vol. 47. P. 223-233
16. Fanti S., Ambrosini V., Tomassetti P. et al. Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET//Biomed. Pharmacother. 2008. Vol. 62. P. 667-671
17. Frilling A., Sotiropoulos G.C., Radtke A. et al. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors//Ann. Surg. 2010. Vol. 252. P. 850-856
18. Gabriel M., Decristoforo C., Kendler D. et al. 68Ga-DOTA-Tyr3octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT//J. Nucl. Med. 2007. Vol. 48. P. 508-518
19. Gibril F., Curtis L.T., Termanini B. et al. Primary cardiac gastrinoma causing Zollinger-Ellison syndrome//Gastroenterology. 1997. Vol. 112 (2). P. 567-574
20. Gibril F., Reynolds J.C., Doppman J.L. et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastaticgastrinomas//Ann. Intern. Med. 1996. Vol. 125. P. 26-34
21. Haug A., Auernhammer C.J., Wängler B. et al. Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours//Eur. J. Nucl. Med. Mol. Imaging. 2009. Vol. 36. P. 765-770
22. Hofmann M., Maecke H., Borner R. et al. Biokinetics and imaging with the somatostatin receptor PET radioligand (68)Ga-DOTATOC: preliminary data//Eur. J. Nucl. Med. 2001. Vol. 28. P. 1751-1757
23. Imani F., Agopian V.G., Auerbach M.S. et al. 18F-FDOPAPET and PET/CT accurately localize pheochromocytomas//J. Nucl. Med. 2009. Vol. 50. P. 513-519
24. Jacobson A.F., Deng H., Lombard J. et al. 123I-meta-iodobenzylguanidine scintigraphy for the detection of neuroblastoma and pheochromocytoma: results of a meta-analysis//J. Clin. Endocrinol. Metab. 2010. Vol. 95. P. 2596-2606
25. Jager P., Chirakal R., Marriott C.J. et al. 6-L-18F-Fluorodihydroxyphenylalanine PET in neuroendocrine tumors: basic aspects and emerging clinical applications//J. Nucl. Med. 2008. Vol. 49. P. 573-586
26. Jindal T., Kumar A., Venkitaraman B. et al. Role of (68)Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids//Korean J. Intern. Med. 2010. Vol. 25. P. 386-391
27. Kaltsas G., Korbonits M., Heintz E. et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors//J. Clin. Endocrinol. Metab. 2001. Vol. 86. P. 895-902
28. Katlas G.A., Mukherjee J.J., Grossman A.B. The value of radiolabelled MIBG and octreotide in the diagnosis and management of neuroendocrine tumours//Ann. Oncol. 2001. Vol. 12. Suppl. 2. S. 47-50
29. Kauhanen S., Seppanen M., Minn H. Fluorine-18-L-dihydroxyphenylalanine (18F-DOPA) positron emission tomography as a tool to localize an insulinoma or b-cell hyperplasia in adult patients//J. Clin. Endocrinol. Metab. 2007. Vol. 92. P. 1237-1244
30. Kauhanen S., Seppaеnen M., Ovaska J. et al. The clinical value of [18F] fluorodihydroxyphenylalanine positron emission tomography in primary diagnosis, staging, and restaging of neuroendocrine tumors//Endocr. Relat. Cancer. 2009. Vol. 16. P. 255-265
31. Koopmans K.P., de Groot J.W., Plukker J.T. et al. 18F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: relation to tumor differentiation//J. Nucl. Med. 2008. Vol. 49. P. 524-531
32. Koopmans K.P., Neels O.C., Kema I.P. et al. Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenylalanine and 11C-5-hydroxy-tryptophan positron emission tomography//J. Clin. Oncol. 2008. Vol. 26. P. 1489-1495
33. Koukouraki S., Strauss L.G., Georgoulias V. et al. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy//Eur. J. Nucl. Med. Mol. Imaging. 2006. Vol. 33. P. 460-466
34. Kowalski J., Henze M., Schuhmacher J. et al. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors//Mol. Imaging Biol. 2003. Vol. 5. P. 42-48
35. Kwekkeboom D., Krenning E.P., de Jong M. Peptide receptor imaging and therapy//J. Nucl. Med. 2000. Vol. 41. P. 1704-1713
36. Kwekkeboom D.J., Teunissen J.J., Bakker W.H. et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors//J. Clin. Oncol. 2005. Vol. 23. P. 2754-2762
37. Lebtahi R., Cadiot G., Sarda L. et al. Clinical impact of somatostatin receptor scintigraphy in the management of patients with neuroendocrine gastroenteropancreatic tumors//J. Nucl. Med. 1997. Vol. 6. P. 853-858
38. McEwan A.J., Shapiro B., Sisson J.C. et al. Radio-iodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors//Semin. Nucl. Med. 1985. Vol. 15. P. 132-153
39. Minn H., Kauhanen S., Seppaenen M. et al. 18F-FDOPA: A Multiple-Target Molecule//J. Nucl. Med. 2009. Vol. 50. P. 1915-1918
40. Mohnike K., Blankenstein O., Minn H. et al. [18F]-DOPA positron emission tomography for preoperative localization in congenital hyperinsulinism//Horm. Res. 2008. Vol. 70. P. 65-72
41. Nielsen J.T., Nielsen B.V., Rehling M. Location of adrenal medullary pheochromocytoma by I-123-metaiodobenzylguanidine SPECT//Clin. Nucl. Med. 1996. Vol. 21. P. 695-699
42. Orlefors H., Sundin A., Ahlstrоm H. et al. Positron Emission Tomography with 5-hydroxytryptophan in Neuroendocrine tumors//J. Clin. Oncol. 1998. Vol. 16. P. 2534-2542
43. Orlefors H., Sundin A., Garske U. et al. Whole-body (11)C-5hydroxytryptophan positron emission tomography as a universal imaging technique for neuroendocrine tumors: comparison with somatostatin recep tor scintigraphy and computed tomography//J. Clin. Endocrinol. Metab. 2005. Vol. 90. P. 3392-3400
44. Prasad V., Ambrosini V., Hommann M. et al. Detection of unknown primary neuroendocrine tumours (CUP-NET) using 68Ga-DOTA-NOC receptor PET/CT//Eur. J. Nucl. Med. Mol. Imaging. 2010. Vol. 37. P. 67-77
45. Putzer D., Gabriel M., Henninger B. et al. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy//J. Nucl. Med. 2009. Vol. 50. P. 1214-1221
46. Raber M.N., Faintuch J., Abbruzzese J.L. et al. Continuous infusion 5-fluorouracil, etoposide and cis-diamminedichloroplatinum in patients with metastaticcarcinomaof unknownprimaryorigin//Ann.Oncol.1991. Vol. 2. P. 519-520
47. Srirajaskanthan R., Kayani I., Quigley A.M. The Role of 68GaDOTATATE PET in Patients with Neuroendocrine Tumors and Negative or Equivocal Findings on 111In-DTPA-Octreotide Scintigraphy//J. Nucl. Med. 2010. Vol. 51. P. 875-882
48. Sundin А. Nuclear imaging of neuroendocrine tumours//Best Pract. Res. Clin. Endocrinol. Metab. 2007. Vol. 21 (1). P. 69-85
49. Taieb D., Tessonnier L., Sebag F. et al. The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas//Clin. Endocrin. (Oxf). 2008. Vol. 69. P. 580-586
50. Termanini B., Gibil F., Reynolds J.C. et al. Value of somatostatin receptor scintigraphy: a prospective study in gastrinoma of its effect on clinical management//Gastroenterology. 1997. Vol. 112. P. 335-347
51. Treglia G., Castaldi P., Rindi G. Diagnostic performance of Gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis//Endocrine. 2012. Vol. 42. P. 80-87
52. Wiseman G.A., Pacak K., O’Dorisio M.S. et al. Usefulness of 123I-MIBG scintigraphy in the evaluation of patients with known or suspected primary or metastatic pheochromocytoma or paraganglioma: results from a prospective multicenter trial//J. Nucl. Med. 2009. Vol. 50. P. 1448-1454
Рецензия
Для цитирования:
Рыжкова Д.В., Тихонова Д.Н., Гринева Е.Н. МЕТОДЫ ЯДЕРНОЙ МЕДИЦИНЫ В ДИАГНОСТИКЕ НЕЙРОЭНДОКРИНЫХ ОПУХОЛЕЙ. Сибирский онкологический журнал. 2013;1(6):56-63.
For citation:
Ryzhkova D.V., Тikhonova D.N., Grineva E.N. Nuclear medicine technology for diagnosisof neuroendocrine tumors. Siberian journal of oncology. 2013;1(6):56-63. (In Russ.)
Просмотров: 616
Послать статью по эл. почте 
